Pictured: Young man hugging his belly suffering from stomach pain while lying in bad at home/iStock, samael334

图为：一名年轻男子躺在家中，肚子疼得紧紧抱住自己的肚子/iStock，samael334

San Francisco-based biotech AltruBio has raised $225 million in an oversubscribed Series B round, the company announced Tuesday. The financing will help the company advance its ulcerative colitis candidate into mid-stage clinical trials.

总部位于旧金山的生物技术公司AltruBio周二宣布，该公司在B轮超额认购中筹集了2.25亿美元。这笔资金将有助于该公司将其溃疡性结肠炎候选人推进中期临床试验。

AltruBio’s candidate ALTB-268 is a first-in-class immune checkpoint enhancer (ICE) PSGL agonist antibody that is currently in a Phase IIa exploratory biomarker study in patients with biologic refractory ulcerative colitis (UC). The readout for the Phase IIa’s primary endpoint of clinical remission per modified Mayo score is expected sometime in the first half of next year..

AltruBio的候选物ALTB-268是一流的免疫检查点增强子（ICE）PSGL激动剂抗体，目前正在生物难治性溃疡性结肠炎（UC）患者的IIa期探索性生物标志物研究中。根据修改后的梅奥评分，IIa期临床缓解主要终点的读数预计将在明年上半年的某个时候公布。。

The Series B funds will support the trial and a Phase IIb study, which will have a primary endpoint of clinical remission in advanced therapy experienced and treatment naïve patients with moderate to serve UC. The biotech expects a readout in the second half of 2026.

B系列基金将支持该试验和IIb期研究，该研究将以晚期治疗经验丰富和未接受治疗的中度至重度UC患者的临床缓解为主要终点。该生物技术公司预计2026年下半年将公布数据。

The Phase I data for ALTB-268 was encouraging as AltruBio reported positive topline data in August 2023. While the company initially gave no hard data points, the data supported the candidate’s progression into Phase II studies.

ALTB-268的第一阶段数据令人鼓舞，因为AltruBio在2023年8月报告了积极的topline数据。虽然该公司最初没有给出确切的数据点，但数据支持候选人进入第二阶段研究。

“With this substantial investment, we are one step closer to bringing our first-in-class, novel immune checkpoint enhancer, ALTB-268, through our ongoing Phase IIa exploratory biomarker study and initiating an additional Phase IIb study while paving the way for potential indication expansion beyond ulcerative colitis,” AltruBio CEO Judy Chou said in a statement..

AltruBio首席执行官朱迪·周（JudyChou）在一份声明中表示：“通过这项巨额投资，我们将通过正在进行的IIa期探索性生物标志物研究，并启动额外的IIb期研究，为溃疡性结肠炎以外的潜在适应症扩展铺平道路，从而使我们的一流新型免疫检查点增强剂ALTB-268更进一步。”。。

The funding round was led by BVF Partners LP and had contributions from new investors, including RA Capital Management, Cormorant Asset Management and Soleus Capital. Existing investors who participated in the Series B included Blackstone Multi-Asset Investing and aMoon Fund.

这轮融资由BVF Partners LP牵头，新投资者提供了资金，包括RA Capital Management、Cormorant Asset Management和Soleus Capital。参与B系列的现有投资者包括黑石多资产投资公司和阿蒙基金。

Formerly known as AbGenomics Holding, the biotech rebranded to AltruBio in 2020. This was due to a “refocusing” of its management and an overall pivot to the autoimmune disease sector. AbGenomics was focused on oncology for a time but halted the Phase I development for one of its candidates in several forms of cancer. .

该生物技术公司原名AbGenomics Holding，于2020年更名为AltruBio。这是由于其管理的“重新聚焦”以及整体转向自身免疫性疾病部门。AbGenomics曾一度专注于肿瘤学，但停止了其多种癌症候选者之一的I期开发。。

The biotech received a $63 million Series A in 2021 to support its development of assets for immunological diseases. The company also received fast-track designation from the FDA for its drug neihulizumab in steroid-refractory acute graft-versus-host disease (SR-aGVHD).

2021年，该生物技术公司获得了6300万美元的a系列资金，用于支持其免疫疾病资产的开发。该公司还因其治疗类固醇难治性急性移植物抗宿主病（SR-aGVHD）的药物奈胡利珠单抗获得了FDA的快速通道指定。

AltruBio is not the only immunology-focused biotech that has secured significant funding this year. In March 2024, precision medicine startup Mirador Therapeutics launched with a $400 million war chest to advance several therapeutic programs targeting immune-mediated inflammatory and fibrotic diseases..

AltruBio并不是今年获得大量资金的唯一一家以免疫学为重点的生物技术公司。2024年3月，精准医学初创公司Mirador Therapeutics以4亿美元的战争资金启动，以推进针对免疫介导的炎症和纤维化疾病的多项治疗计划。。

Earlier this month, Attovia Therapeutics raised $105 million in a Series B to advance several candidates to treat immune-mediated diseases, atopic dermatitis and other pruritic diseases.

本月早些时候，Attovia Therapeutics在B系列中筹集了1.05亿美元，以推动几名候选人治疗免疫介导的疾病，特应性皮炎和其他瘙痒性疾病。

Tyler Patchen is a staff writer at BioSpace. You can reach him at tyler.patchen@biospace.com. Follow him on LinkedIn.

泰勒·帕肯（Tyler Patchen）是BioSpace的一名全职作家。你可以通过tyler.patchen@biospace.com.在LinkedIn上关注他。